These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 34575045)
1. BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects. Vicenti I; Gatti F; Scaggiante R; Boccuto A; Zago D; Basso M; Dragoni F; Parisi SG; Zazzi M Life (Basel); 2021 Aug; 11(9):. PubMed ID: 34575045 [TBL] [Abstract][Full Text] [Related]
2. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. Serrano-Conde E; Leyva A; Fuentes A; de Salazar A; Chueca N; Pérez-Castro S; Regueiro B; Rojas A; Mendoza J; Rojas J; García F Transbound Emerg Dis; 2022 Sep; 69(5):2649-2655. PubMed ID: 34910373 [TBL] [Abstract][Full Text] [Related]
3. Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. Vicenti I; Basso M; Gatti F; Scaggiante R; Boccuto A; Zago D; Modolo E; Dragoni F; Parisi SG; Zazzi M Int J Infect Dis; 2021 Nov; 112():40-44. PubMed ID: 34481967 [TBL] [Abstract][Full Text] [Related]
4. Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination. Bonura F; Genovese D; Amodio E; Calamusa G; Sanfilippo GL; Cacioppo F; Giammanco GM; De Grazia S; Ferraro D Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746482 [TBL] [Abstract][Full Text] [Related]
5. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients. Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467 [TBL] [Abstract][Full Text] [Related]
6. Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection. Vicenti I; Gatti F; Scaggiante R; Boccuto A; Zago D; Basso M; Dragoni F; Zazzi M; Parisi SG Int J Infect Dis; 2021 Jul; 108():176-178. PubMed ID: 34022329 [TBL] [Abstract][Full Text] [Related]
7. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed? Stellini R; Gianello R; Gomarasca W Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649 [TBL] [Abstract][Full Text] [Related]
8. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S Front Immunol; 2021; 12():793191. PubMed ID: 34975897 [TBL] [Abstract][Full Text] [Related]
9. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy). Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E; Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961 [TBL] [Abstract][Full Text] [Related]
11. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493 [TBL] [Abstract][Full Text] [Related]
12. Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection. Vicenti I; Basso M; Dragoni F; Gatti F; Scaggiante R; Fiaschi L; Parisi SG; Zazzi M Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455329 [TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186 [TBL] [Abstract][Full Text] [Related]
14. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study. Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069 [TBL] [Abstract][Full Text] [Related]
15. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162 [TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers. Benning L; Morath C; Bartenschlager M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schaier M; Klein K; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Speer C Clin Microbiol Infect; 2022 Jul; 28(7):1024.e7-1024.e12. PubMed ID: 35124261 [TBL] [Abstract][Full Text] [Related]
17. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P Front Immunol; 2022; 13():816389. PubMed ID: 35464418 [TBL] [Abstract][Full Text] [Related]
18. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252 [TBL] [Abstract][Full Text] [Related]
19. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Jahrsdörfer B; Fabricius D; Scholz J; Ludwig C; Grempels A; Lotfi R; Körper S; Adler G; Schrezenmeier H Front Immunol; 2021; 12():743422. PubMed ID: 34659239 [TBL] [Abstract][Full Text] [Related]
20. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. Noori M; Nejadghaderi SA; Arshi S; Carson-Chahhoud K; Ansarin K; Kolahi AA; Safiri S Rev Med Virol; 2022 Mar; 32(2):e2277. PubMed ID: 34286893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]